<DOC>
	<DOC>NCT00586950</DOC>
	<brief_summary>The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.</brief_summary>
	<brief_title>123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Adult hemodialysis patients with one or more of the following 10 risk factors for coronary heart disease Hypertension Diabetes mellitus Hyperlipidemia Obliterative arteriosclerosis in the lower extremities Smoker Family history of juvenile coronary artery disease History of ischemic stroke History of heart failure requiring hospitalization Within 3 months after initiation of hemodialysis therapy Dialysis hypotension Hemodialysis patients who meet any one of the following conditions will be excluded. Peritoneal dialysis Severe valvular disorder requiring treatment Diagnosis of hypertrophic cardiomyopathy(HCM) or dilated cardiomyopathy(DCM) before start of dialysis History of revascularization(PCI, CABG) or prior diagnosis of myocardial infarction Hypersensitivity to BMIPP or its analogue Judged unsuitable for the study for any other reasons by physicians.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Myocardial Free Fatty Acid metabolism</keyword>
	<keyword>High risk patients</keyword>
	<keyword>End-stage renal failure</keyword>
	<keyword>Cardiovascular events</keyword>
	<keyword>prognosis</keyword>
</DOC>